Lindbrook Capital, LLC Reata Pharmaceuticals Inc Transaction History

Lindbrook Capital, LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 28, 2023	SELL	$79.22 - $105.37 $79 - $105	-1 Reduced 0.69%	144 $14,000
Q1 2023 Apr 26, 2023	BUY	$30.85 - $93.17 $2,036 - $6,149	66 Added 83.54%	145 $13,000
Q4 2022 Jan 24, 2023	BUY	$22.15 - $42.11 $132 - $252	6 Added 8.22%	79 $0
Q3 2022 Nov 10, 2022	BUY	$19.41 - $36.49 $465 - $875	24 Added 48.98%	73 $2,000
Q2 2022 Aug 01, 2022	BUY	$20.71 - $36.5 $497 - $876	24 Added 96.0%	49 $1,000
Q1 2022 Apr 21, 2022	BUY	$24.12 - $39.6 $603 - $990	25 New	25 $1,000
Q4 2021 Jan 18, 2022	SELL	$25.61 - $110.96 $665 - $2,884	-26 Closed	0 $0
Q3 2021 Nov 05, 2021	SELL	$100.0 - $143.02 $500 - $715	-5 Reduced 16.13%	26 $3,000
Q2 2021 Jul 27, 2021	SELL	$78.27 - $151.29 $1,408 - $2,723	-18 Reduced 36.73%	31 $4,000
Q4 2020 Jan 27, 2021	BUY	$102.03 - $184.62 $2,958 - $5,353	29 Added 145.0%	49 $6,000
Q3 2020 Nov 03, 2020	BUY	$93.53 - $163.34 $1,870 - $3,266	20 New	20 $2,000
Q4 2019 Jan 27, 2020	SELL	$74.57 - $217.92 $29,827 - $87,168	-400 Closed	0 $0
Q3 2019 Oct 31, 2019	BUY	$71.26 - $95.75 $28,504 - $38,300	400 New	400 $32,000
Q2 2019 Jul 24, 2019	SELL	$77.72 - $94.35 $38,860 - $47,175	-500 Closed	0 $0
Q1 2019 Apr 23, 2019	SELL	$51.9 - $101.79 $12,975 - $25,447	-250 Reduced 33.33%	500 $42,000
Q4 2018 Feb 07, 2019	BUY	$48.76 - $76.44 $36,570 - $57,330	750 New	750 $42,000

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.